Points of therapeutic intervention along the wnt signaling pathway in hepatocellular carcinoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 6, 2011, Pages 549-559

  Nambotin, Sarah B ^a   Wands, Jack R ^a   Kim, Miran ^a  

^a Liver Research Center Brown University Medical School   (United States)

Author keywords

Frizzled; Hepatocellular carcinoma; Molecular target; Targeted therapy; WNT; catenin

Indexed keywords

BETA CATENIN; CASEIN KINASE I; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DIETHYLNITROSAMINE; DISHEVELLED PROTEIN; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE 1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LYMPHOID ENHANCER FACTOR 1; MONOCLONAL ANTIBODY; PROTEIN KINASE C; STRESS ACTIVATED PROTEIN KINASE; T CELL FACTOR PROTEIN; WNT PROTEIN; WNT1 PROTEIN;

APOPTOSIS; CANCER CELL CULTURE; CANCER MORTALITY; CELL CYCLE; CELL DESTRUCTION; CELL DISRUPTION; CELL MIGRATION; CELL MOTILITY; CELL POLARITY; CELL PROLIFERATION; CHEMOEMBOLIZATION; DNA BINDING MOTIF; DNA METHYLATION; EMBRYO DEVELOPMENT; ENZYME ACTIVATION; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN TARGETING; REVIEW; TRANSARTERIAL CHEMOEMBOLIZATION; TUMOR GROWTH;

EID: 79959287290     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011796011019     Document Type: Review

References (140)

1. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer, 2010, 127(12), 2893-2917.
2. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T.F.; Galle, P.R.; Seitz, J.F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359(4), 378-390.
3. Llovet, J.M.; Bruix, J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 2008, 48(4), 1312-1327.
4. Whittaker, S.; Marais, R.; Zhu, A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 2010, 29(36), 4989-5005.
5. Segditsas, S.; Tomlinson, I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene, 2006, 25(57), 7531-7537.
6. Klarmann, G.J.; Decker, A.; Farrar, W.L. Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics, 2008, 3(2), 59-63.
7. Larue, L.; Delmas, V. The WNT/Beta-catenin pathway in melanoma. Front. Biosci., 2006, 11, 733-742.
8. Daniel, V.C.; Peacock, C.D.; Watkins, D.N. Developmental signalling pathways in lung cancer. Respirology, 2006, 11(3), 234-240.
9. Yang-Snyder, J.; Miller, J.R.; Brown, J.D.; Lai, C.J.; Moon, R.T. A frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr. Biol., 1996, 6(10), 1302-1306.
10. Mao, J.; Wang, J.; Liu, B.; Pan, W.; Farr, G.H., 3rd; Flynn, C.; Yuan, H.; Takada, S.; Kimelman, D.; Li, L.; Wu, D. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol. Cell, 2001, 7(4), 801-809.
11. Tamai, K.; Semenov, M.; Kato, Y.; Spokony, R.; Liu, C.; Katsuyama, Y.; Hess, F.; Saint-Jeannet, J.P.; He, X. LDL-receptorrelated proteins in Wnt signal transduction. Nature, 2000, 407(6803), 530-535.
12. Xu, Q.; Wang, Y.; Dabdoub, A.; Smallwood, P.M.; Williams, J.; Woods, C.; Kelley, M.W.; Jiang, L.; Tasman, W.; Zhang, K.; Nathans, J. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell, 2004, 116(6), 883-895.
13. Kim, K.A.; Kakitani, M.; Zhao, J.; Oshima, T.; Tang, T.; Binnerts, M.; Liu, Y.; Boyle, B.; Park, E.; Emtage, P.; Funk, W.D.; Tomizuka, K. Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science, 2005, 309(5738), 1256-1259.
14. Oishi, I.; Suzuki, H.; Onishi, N.; Takada, R.; Kani, S.; Ohkawara, B.; Koshida, I.; Suzuki, K.; Yamada, G.; Schwabe, G.C.; Mundlos, S.; Shibuya, H.; Takada, S.; Minami, Y. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells, 2003, 8(7), 645-654.
15. Lu, W.; Yamamoto, V.; Ortega, B.; Baltimore, D. Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite outgrowth. Cell, 2004, 119(1), 97-108.
16. Keeble, T.R.; Halford, M.M.; Seaman, C.; Kee, N.; Macheda, M.; Anderson, R.B.; Stacker, S.A.; Cooper, H.M. The Wnt receptor Ryk is required for Wnt5a-mediated axon guidance on the contralateral side of the corpus callosum. J. Neurosci., 2006, 26(21), 5840-5848.
17. Finch, P.W.; He, X.; Kelley, M.J.; Uren, A.; Schaudies, R.P.; Popescu, N.C.; Rudikoff, S.; Aaronson, S.A.; Varmus, H.E.; Rubin, J.S. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc. Natl. Acad. Sci. U S A, 1997, 94(13), 6770-6775.
18. Rattner, A.; Hsieh, J.C.; Smallwood, P.M.; Gilbert, D.J.; Copeland, N.G.; Jenkins, N.A.; Nathans, J. A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc. Natl. Acad. Sci. U S A, 1997, 94(7), 2859-2863.
19. Bouwmeester, T.; Kim, S.; Sasai, Y.; Lu, B.; De Robertis, E.M. Cerberus is a head-inducing secreted factor expressed in the anterior endoderm of Spemann's organizer. Nature, 1996, 382(6592), 595-601.
20. Piccolo, S.; Agius, E.; Leyns, L.; Bhattacharyya, S.; Grunz, H.; Bouwmeester, T.; De Robertis, E.M. The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals. Nature, 1999, 397(6721), 707-710.
21. Hsieh, J.C.; Kodjabachian, L.; Rebbert, M.L.; Rattner, A.; Smallwood, P.M.; Samos, C.H.; Nusse, R.; Dawid, I.B.; Nathans, J. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature, 1999, 398(6726), 431-436.
22. Glinka, A.; Wu, W.; Delius, H.; Monaghan, A.P.; Blumenstock, C.; Niehrs, C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature, 1998, 391(6665), 357-362.
23. Semenov, M.V.; Tamai, K.; Brott, B.K.; Kuhl, M.; Sokol, S.; He, X. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr. Biol., 2001, 11(12), 951-961.
24. Mao, B.; Wu, W.; Davidson, G.; Marhold, J.; Li, M.; Mechler, B.M.; Delius, H.; Hoppe, D.; Stannek, P.; Walter, C.; Glinka, A.; Niehrs, C. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature, 2002, 417(6889), 664-667.
25. Wong, H.C.; Bourdelas, A.; Krauss, A.; Lee, H.J.; Shao, Y.; Wu, D.; Mlodzik, M.; Shi, D.L.; Zheng, J. Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the Cterminal region of Frizzled. Mol. Cell, 2003, 12(5), 1251-1260.
26. Umbhauer, M.; Djiane, A.; Goisset, C.; Penzo-Mendez, A.; Riou, J.F.; Boucaut, J.C.; Shi, D.L. The C-terminal cytoplasmic Lys-thr- X-X-X-Trp motif in frizzled receptors mediates Wnt/beta-catenin signalling. EMBO J., 2000, 19(18), 4944-4954.
27. Axelrod, J.D.; Miller, J.R.; Shulman, J.M.; Moon, R.T.; Perrimon, N. Differential recruitment of Dishevelled provides signaling specificity in the planar cell polarity and Wingless signaling pathways. Genes Dev., 1998, 12(16), 2610-2622.
28. Willert, K.; Brink, M.; Wodarz, A.; Varmus, H.; Nusse, R. Casein kinase 2 associates with and phosphorylates dishevelled. EMBO J., 1997, 16(11), 3089-3096.
29. DeMarais, A.A.; Moon, R.T. The armadillo homologs beta-catenin and plakoglobin are differentially expressed during early development of Xenopus laevis. Dev. Biol., 1992, 153(2), 337-346.
30. McCrea, P.D.; Gumbiner, B.M. Purification of a 92-kDa cytoplasmic protein tightly associated with the cell-cell adhesion molecule E-cadherin (uvomorulin). Characterization and extractability of the protein complex from the cell cytostructure. J. Biol. Chem., 1991, 266(7), 4514-4520
31. Amit, S.; Hatzubai, A.; Birman, Y.; Andersen, J.S.; Ben-Shushan, E.; Mann, M.; Ben-Neriah, Y.; Alkalay, I. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev., 2002, 16(9), 1066-1076.
32. Yost, C.; Torres, M.; Miller, J.R.; Huang, E.; Kimelman, D.; Moon, R.T. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev., 1996, 10(12), 1443-1454.
33. Aberle, H.; Bauer, A.; Stappert, J.; Kispert, A.; Kemler, R. betacatenin is a target for the ubiquitin-proteasome pathway. EMBO J., 1997, 16(13), 3797-3804.
34. Orford, K.; Crockett, C.; Jensen, J.P.; Weissman, A.M.; Byers, S.W. Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. J. Biol. Chem., 1997, 272(40), 24735-24738.
35. Ikeda, S.; Kishida, S.; Yamamoto, H.; Murai, H.; Koyama, S.; Kikuchi, A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J., 1998, 17(5), 1371-1384.
36. Rubinfeld, B.; Souza, B.; Albert, I.; Muller, O.; Chamberlain, S.H.; Masiarz, F.R.; Munemitsu, S.; Polakis, P. Association of the APC gene product with beta-catenin. Science, 1993, 262(5140), 1731-1734.
37. Brantjes, H.; Roose, J.; van De Wetering, M.; Clevers, H. All Tcf HMG box transcription factors interact with Groucho-related corepressors. Nucleic Acids Res., 2001, 29(7), 1410-1419.
38. Billin, A.N.; Thirlwell, H.; Ayer, D.E. Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator. Mol. Cell. Biol., 2000, 20(18), 6882-6890.
39. Gradl, D.; Konig, A.; Wedlich, D. Functional diversity of Xenopus lymphoid enhancer factor/T-cell factor transcription factors relies on combinations of activating and repressing elements. J. Biol. Chem., 2002, 277(16), 14159-14171.
40. Van de Wetering, M.; Castrop, J.; Korinek, V.; Clevers, H. Extensive alternative splicing and dual promoter usage generate Tcf-1 protein isoforms with differential transcription control properties. Mol. Cell. Biol., 1996, 16(3), 745-752.
41. Roel, G.; van den Broek, O.; Spieker, N.; Peterson-Maduro, J.; Destree, O. Tcf-1 expression during Xenopus development. Gene Expr. Patterns, 2003, 3(2), 123-126.
42. Kishida, S.; Yamamoto, H.; Hino, S.; Ikeda, S.; Kishida, M.; Kikuchi, A. DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability. Mol. Cell. Biol., 1999, 19(6), 4414-4422.
43. Smalley, M.J.; Sara, E.; Paterson, H.; Naylor, S.; Cook, D.; Jayatilake, H.; Fryer, L.G.; Hutchinson, L.; Fry, M.J.; Dale, T.C. Interaction of axin and Dvl-2 proteins regulates Dvl-2-stimulated TCFdependent transcription. EMBO J., 1999, 18(10), 2823-2835.
44. Zeng, G.; Apte, U.; Cieply, B.; Singh, S.; Monga, S.P. siRNAmediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia, 2007, 9(11), 951-959.
45. Levy, L.; Wei, Y.; Labalette, C.; Wu, Y.; Renard, C.A.; Buendia, M.A.; Neuveut, C. Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction. Mol. Cell. Biol., 2004, 24(8), 3404-3414.
46. Takemaru, K.I.; Moon, R.T. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J. Cell. Biol., 2000, 149(2), 249-254.
47. Kramps, T.; Peter, O.; Brunner, E.; Nellen, D.; Froesch, B.; Chatterjee, S.; Murone, M.; Zullig, S.; Basler, K. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell, 2002, 109(1), 47-60.
48. Townsley, F.M.; Cliffe, A.; Bienz, M. Pygopus and Legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function. Nat. Cell Biol., 2004, 6(7), 626-633.
49. Andrews, P.G.; He, Z.; Popadiuk, C.; Kao, K.R. The transcriptional activity of Pygopus is enhanced by its interaction with cAMPresponse- element-binding protein (CREB)-binding protein. Biochem. J., 2009, 422(3), 493-501.
50. Barker, N.; Hurlstone, A.; Musisi, H.; Miles, A.; Bienz, M.; Clevers, H. The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation. EMBO J., 2001, 20(17), 4935-4943.
51. He, T.C.; Sparks, A.B.; Rago, C.; Hermeking, H.; Zawel, L.; da Costa, L.T.; Morin, P.J.; Vogelstein, B.; Kinzler, K.W. Identification of c-MYC as a target of the APC pathway. Science, 1998, 281(5382), 1509-1512.
52. Shtutman, M.; Zhurinsky, J.; Simcha, I.; Albanese, C.; D'Amico, M.; Pestell, R.; Ben-Ze'ev, A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. U S A, 1999, 96(10), 5522-5527.
53. Zhang, T.; Otevrel, T.; Gao, Z.; Gao, Z.; Ehrlich, S.M.; Fields, J.Z.; Boman, B.M. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res., 2001, 61(24), 8664-8667.
54. Brabletz, T.; Jung, A.; Dag, S.; Hlubek, F.; Kirchner, T. betacatenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol., 1999, 155(4), 1033-1038.
55. Salmanian, S.; Najafi, S.M.; Rafipour, M.; Arjomand, M.R.; Shahheydari, H.; Ansari, S.; Kashkooli, L.; Rasouli, S.J.; Jazi, M.S.; Minaei, T. Regulation of GSK-3beta and beta-Catenin by Galphaq in HEK293T cells. Biochem. Biophys. Res. Commun, 2010, 395(4), 577-582.
56. Jernigan, K.K.; Cselenyi, C.S.; Thorne, C.A.; Hanson, A.J.; Tahinci, E.; Hajicek, N.; Oldham, W.M.; Lee, L.A.; Hamm, H.E.; Hepler, J.R.; Kozasa, T.; Linder, M.E.; Lee, E. Gbetagamma activates GSK3 to promote LRP6-mediated beta-catenin transcriptional activity. Sci. Signal., 2010, 3(121), ra37.
57. Qin, X.; Zhang, H.; Zhou, X.; Wang, C.; Zhang, H.; Zhang, X.; Ye, L. Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells. Transl. Res., 2007, 150(5), 281-294.
58. Merle, P.; de la Monte, S.; Kim, M.; Herrmann, M.; Tanaka, S.; Von Dem Bussche, A.; Kew, M.C.; Trepo, C.; Wands, J.R. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology, 2004, 127(4), 1110-1122.
59. de La Coste, A.; Romagnolo, B.; Billuart, P.; Renard, C.A.; Buendia, M.A.; Soubrane, O.; Fabre, M.; Chelly, J.; Beldjord, C.; Kahn, A.; Perret, C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. U S A, 1998, 95(15), 8847-8851.
60. Nhieu, J.T.; Renard, C.A.; Wei, Y.; Cherqui, D.; Zafrani, E.S.; Buendia, M.A. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am. J. Pathol., 1999, 155(3), 703-710.
61. Kondo, Y.; Kanai, Y.; Sakamoto, M.; Genda, T.; Mizokami, M.; Ueda, R.; Hirohashi, S. Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma. Jpn J. Cancer Res., 1999, 90(12), 1301-1309.
62. Miyoshi, Y.; Iwao, K.; Nagasawa, Y.; Aihara, T.; Sasaki, Y.; Imaoka, S.; Murata, M.; Shimano, T.; Nakamura, Y. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res., 1998, 58(12), 2524-2527.
63. Huang, H.; Fujii, H.; Sankila, A.; Mahler-Araujo, B.M.; Matsuda, M.; Cathomas, G.; Ohgaki, H. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am. J. Pathol., 1999, 155(6), 1795-1801.
64. Taniguchi, K.; Roberts, L.R.; Aderca, I.N.; Dong, X.; Qian, C.; Murphy, L.M.; Nagorney, D.M.; Burgart, L.J.; Roche, P.C.; Smith, D.I.; Ross, J.A.; Liu, W. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene, 2002, 21(31), 4863-4871.
65. Kim, Y.D.; Park, C.H.; Kim, H.S.; Choi, S.K.; Rew, J.S.; Kim, D.Y.; Koh, Y.S.; Jeung, K.W.; Lee, K.H.; Lee, J.S.; Juhng, S.W.; Lee, J.H. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma. J. Gastroenterol. Hepatol., 2008, 23(1), 110-118.
66. Satoh, S.; Daigo, Y.; Furukawa, Y.; Kato, T.; Miwa, N.; Nishiwaki, T.; Kawasoe, T.; Ishiguro, H.; Fujita, M.; Tokino, T.; Sasaki, Y.; Imaoka, S.; Murata, M.; Shimano, T.; Yamaoka, Y.; Nakamura, Y. AXIN1 mutations in hepatocellular carcinomas, and growth sup pression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet., 2000, 24(3), 245-250.
67. Park, J.Y.; Park, W.S.; Nam, S.W.; Kim, S.Y.; Lee, S.H.; Yoo, N.J.; Lee, J.Y.; Park, C.K. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int., 2005, 25(1), 70-76.
68. Zulehner, G.; Mikula, M.; Schneller, D.; van Zijl, F.; Huber, H.; Sieghart, W.; Grasl-Kraupp, B.; Waldhor, T.; Peck-Radosavljevic, M.; Beug, H.; Mikulits, W. Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. Am. J. Pathol., 2010, 176(1), 472-481.
69. Cui, J.; Zhou, X.; Liu, Y.; Tang, Z.; Romeih, M. Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. J. Gastroenterol. Hepatol., 2003, 18(3), 280-287.
70. Bengochea, A.; de Souza, M.M.; Lefrancois, L.; Le Roux, E.; Galy, O.; Chemin, I.; Kim, M.; Wands, J.R.; Trepo, C.; Hainaut, P.; Scoazec, J.Y.; Vitvitski, L.; Merle, P. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br. J. Cancer, 2008, 99(1), 143-150.
71. Huang, J.; Zhang, Y.L.; Teng, X.M.; Lin, Y.; Zheng, D.L.; Yang, P.Y.; Han, Z.G. Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC Cancer, 2007, 7, 126.
72. Deng, Y.; Yu, B.; Cheng, Q.; Jin, J.; You, H.; Ke, R.; Tang, N.; Shen, Q.; Shu, H.; Yao, G.; Zhang, Z.; Qin, W. Epigenetic silencing of WIF-1 in hepatocellular carcinomas. J. Cancer Res. Clin. Oncol., 2011, 136(8), 1161-1167.
73. Kim, M.; Lee, H.C.; Tsedensodnom, O.; Hartley, R.; Lim, Y.S.; Yu, E.; Merle, P.; Wands, J.R. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J. Hepatol., 2008, 48(5), 780-791.
74. Ding, Z.; Qian, Y.B.; Zhu, L.X.; Xiong, Q.R. Promoter methylation and mRNA expression of DKK-3 and WIF-1 in hepatocellular carcinoma. World J. Gastroenterol., 2009, 15(21), 2595-2601.
75. Pang, R.; Yuen, J.; Yuen, M.F.; Lai, C.L.; Lee, T.K.; Man, K.; Poon, R.T.; Fan, S.T.; Wong, C.M.; Ng, I.O.; Kwong, Y.L.; Tse, E. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene, 2004, 23(23), 4182-4186.
76. Shibata, T.; Chuma, M.; Kokubu, A.; Sakamoto, M.; Hirohashi, S. EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology, 2003, 38(1), 178-186.
77. Chan, D.W.; Chan, C.Y.; Yam, J.W.; Ching, Y.P.; Ng, I.O. Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. Gastroenterology, 2006, 131(4), 1218-1227.
78. Shih, Y.L.; Shyu, R.Y.; Hsieh, C.B.; Lai, H.C.; Liu, K.Y.; Chu, T.Y.; Lin, Y.W. Promoter methylation of the secreted frizzledrelated protein 1 gene SFRP1 is frequent in hepatocellular carcinoma. Cancer, 2006, 107(3), 579-590.
79. Jia, Y.; Yang, Y.; Liu, S.; Herman, J.G.; Lu, F.; Guo, M. SOX17 antagonizes WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Epigenetics, 2010, 5(8), 1-7.
80. Takagi, H.; Sasaki, S.; Suzuki, H.; Toyota, M.; Maruyama, R.; Nojima, M.; Yamamoto, H.; Omata, M.; Tokino, T.; Imai, K.; Shinomura, Y. Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J. Gastroenterol., 2008, 43(5), 378-389.
81. Tsedensodnom, O.; Koga, H.; Rosenberg, S.; Nambotin, S.B.; Carroll, J.; Wands, J.; Kim, M. Identification of T-Cell Factor-4 isoforms that contribute to the malignant phenotype of hepatocellular carcinoma cells. Exp. Cell Res., 2011, 317(7), 920-931.
82. Yamashita, T.; Budhu, A.; Forgues, M.; Wang, X.W. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res., 2007, 67(22), 10831-10839.
83. Yamashita, T.; Ji, J.; Budhu, A.; Forgues, M.; Yang, W.; Wang, H.Y.; Jia, H.; Ye, Q.; Qin, L.X.; Wauthier, E.; Reid, L.M.; Minato, H.; Honda, M.; Kaneko, S.; Tang, Z.Y.; Wang, X.W. EpCAMpositive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology, 2009, 136(3), 1012-1024.
84. Yang, W.; Yan, H.X.; Chen, L.; Liu, Q.; He, Y.Q.; Yu, L.X.; Zhang, S.H.; Huang, D.D.; Tang, L.; Kong, X.N.; Chen, C.; Liu, S.Q.; Wu, M.C.; Wang, H.Y. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res., 2008, 68(11), 4287-4295.
85. Noda, T.; Nagano, H.; Takemasa, I.; Yoshioka, S.; Murakami, M.; Wada, H.; Kobayashi, S.; Marubashi, S.; Takeda, Y.; Dono, K.; Umeshita, K.; Matsuura, N.; Matsubara, K.; Doki, Y.; Mori, M.; Monden, M. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br. J. Cancer, 2009, 100(10), 1647-1658.
86. Behari, J.; Zeng, G.; Otruba, W.; Thompson, M.D.; Muller, P.; Micsenyi, A.; Sekhon, S.S.; Leoni, L.; Monga, S.P. R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. J. Hepatol., 2007, 46(5), 849-857.
87. Inoue, T.; Murano, M.; Yoda, Y.; Kuramoto, T.; Kakimoto, K.; Ishida, K.; Kawakami, K.; Abe, Y.; Morita, E.; Murano, N.; Tokioka, S.; Maemura, K.; Umegaki, E.; Higuchi, K. R-etodolac induces E-cadherin and suppresses colitis-related mouse colon tumorigenesis. Oncol. Rep., 2010, 24(6), 1487-1492.
88. Merle, P.; Kim, M.; Herrmann, M.; Gupte, A.; Lefrancois, L.; Califano, S.; Trepo, C.; Tanaka, S.; Vitvitski, L.; de la Monte, S.; Wands, J.R. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J. Hepatol., 2005, 43(5), 854-862.
89. Longato, L.; de la Monte, S.; Kuzushita, N.; Horimoto, M.; Rogers, A.B.; Slagle, B.L.; Wands, J.R. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology, 2009, 49(6), 1935-1943.
90. Rhee, C.S.; Sen, M.; Lu, D.; Wu, C.; Leoni, L.; Rubin, J.; Corr, M.; Carson, D.A. Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene, 2002, 21(43), 6598-6605.
91. Huang, C.L.; Liu, D.; Ishikawa, S.; Nakashima, T.; Nakashima, N.; Yokomise, H.; Kadota, K.; Ueno, M. Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur. J. Cancer, 2008, 44(17), 2680-2688.
92. Lin, S.M.; Lin, C.J.; Lin, C.C.; Hsu, C.W.; Chen, Y.C. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology, 2004, 127(6), 1714-1723.
93. Wei, W.; Chua, M.S.; Grepper, S.; So, S.K. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol. Cancer, 2009, 8, 76.
94. Lee, H.H.; Uen, Y.H.; Tian, Y.F.; Sun, C.S.; Sheu, M.J.; Kuo, H.T.; Koay, L.B.; Lin, C.Y.; Tzeng, C.C.; Cheng, C.J.; Tang, L.Y.; Tsai, S.L.; Wang, A.H. Wnt-1 protein as a prognostic biomarker for hepatitis B-related and hepatitis C-related hepatocellular carcinoma after surgery. Cancer Epidemiol. Biomarkers Prev., 2009, 18(5), 1562-1569.
95. You, L.; He, B.; Uematsu, K.; Xu, Z.; Mazieres, J.; Lee, A.; McCormick, F.; Jablons, D.M. Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res., 2004, 64(10), 3474-3478.
96. Uematsu, K.; Kanazawa, S.; You, L.; He, B.; Xu, Z.; Li, K.; Peterlin, B.M.; McCormick, F.; Jablons, D.M. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res., 2003, 63(15), 4547-4551.
97. Hung, A.Y.; Sheng, M. PDZ domains: structural modules for protein complex assembly. J. Biol. Chem., 2002, 277(8), 5699-5702.
98. Zhang, Y.; Appleton, B.A.; Wiesmann, C.; Lau, T.; Costa, M.; Hannoush, R.N.; Sidhu, S.S. Inhibition of Wnt signaling by Dishevelled PDZ peptides. Nat. Chem. Biol., 2009, 5(4), 217-219.
99. Shan, J.; Shi, D.L.; Wang, J.; Zheng, J. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry, 2005, 44(47), 15495-15503.
100. Shan, J.; Zheng, J.J. Optimizing Dvl PDZ domain inhibitor by exploring chemical space. J. Comput. Aided Mol. Des., 2009, 23(1), 37-47.
101. Grandy, D.; Shan, J.; Zhang, X.; Rao, S.; Akunuru, S.; Li, H.; Zhang, Y.; Alpatov, I.; Zhang, X.A.; Lang, R.A.; Shi, D.L.; Zheng, J.J. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J. Biol. Chem., 2009, 284(24), 16256-16263.
102. Fujii, N.; You, L.; Xu, Z.; Uematsu, K.; Shan, J.; He, B.; Mikami, I.; Edmondson, L.R.; Neale, G.; Zheng, J.; Guy, R.K.; Jablons, D.M. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res., 2007, 67(2), 573-579.
103. Nambotin, S.B.; Lefrancois, L.; Sainsily, X.; Berthillon, P.; Kim, M.; Wands, J.R.; Chevallier, M.; Jalinot, P.; Scoazec, J.Y.; Trepo, C.; Zoulim, F.; Merle, P. Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J. Hepatol., 2010, 54(2), 288-299.
104. Shih, Y.L.; Hsieh, C.B.; Lai, H.C.; Yan, M.D.; Hsieh, T.Y.; Chao, Y.C.; Lin, Y.W. SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int. J. Cancer, 2007, 121(5), 1028-1035.
105. Hu, J.; Dong, A.; Fernandez-Ruiz, V.; Shan, J.; Kawa, M.; Martinez-Anso, E.; Prieto, J.; Qian, C. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Cancer Res., 2009, 69(17), 6951-6959.
106. Pesonen, S.; Kangasniemi, L.; Hemminki, A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol. Pharm., 2010, 8(1), 12-28.
107. Xue, X.B.; Xiao, C.W.; Zhang, H.; Lu, A.G.; Gao, W.; Zhou, Z.Q.; Guo, X.L.; Zhong, M.A.; Yang, Y.; Wang, C.J. Oncolytic adenovirus SG600-IL24 selectively kills hepatocellular carcinoma cell lines. World J. Gastroenterol., 2010, 16(37), 4677-4684.
108. Brunori, M.; Malerba, M.; Kashiwazaki, H.; Iggo, R. Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J. Virol., 2001, 75(6), 2857-2865.
109. Yau, T.O.; Chan, C.Y.; Chan, K.L.; Lee, M.F.; Wong, C.M.; Fan, S.T.; Ng, I.O. HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing. Oncogene, 2005, 24(9), 1607-1614.
110. Chen, W.; Hu, L.A.; Semenov, M.V.; Yanagawa, S.; Kikuchi, A.; Lefkowitz, R.J.; Miller, W.E. beta-Arrestin1 modulates lymphoid enhancer factor transcriptional activity through interaction with phosphorylated dishevelled proteins. Proc. Natl. Acad. Sci. U S A, 2001, 98(26), 14889-14894.
111. Chen, W.; ten Berge, D.; Brown, J.; Ahn, S.; Hu, L.A.; Miller, W.E.; Caron, M.G.; Barak, L.S.; Nusse, R.; Lefkowitz, R.J. Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5Astimulated endocytosis of Frizzled 4. Science, 2003, 301(5638), 1391-1394.
112. Bryja, V.; Cajanek, L.; Grahn, A.; Schulte, G. Inhibition of endocytosis blocks Wnt signalling to beta-catenin by promoting dishevelled degradation. Acta Physiol. (Oxf), 2007, 190(1), 55-61.
113. Gagliardi, M.; Piddini, E.; Vincent, J.P. Endocytosis: a positive or a negative influence on Wnt signalling? Traffic, 2008, 9(1), 1-9.
114. Chen, B.; Dodge, M.E.; Tang, W.; Lu, J.; Ma, Z.; Fan, C.W.; Wei, S.; Hao, W.; Kilgore, J.; Williams, N.S.; Roth, M.G.; Amatruda, J.F.; Chen, C.; Lum, L. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol., 2009, 5(2), 100-107.
115. Takada, R.; Satomi, Y.; Kurata, T.; Ueno, N.; Norioka, S.; Kondoh, H.; Takao, T.; Takada, S. Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev. Cell, 2006, 11(6), 791-801.
116. Lepourcelet, M.; Chen, Y.N.; France, D.S.; Wang, H.; Crews, P.; Petersen, F.; Bruseo, C.; Wood, A.W.; Shivdasani, R.A. Smallmolecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell, 2004, 5(1), 91-102.
117. Wei, W.; Chua, M.S.; Grepper, S.; So, S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int. J. Cancer, 2009, 126(10), 2426-2436.
118. Graham, T.A.; Weaver, C.; Mao, F.; Kimelman, D.; Xu, W. Crystal structure of a beta-catenin/Tcf complex. Cell, 2000, 103(6), 885-896.
119. Huber, A.H.; Weis, W.I. The structure of the beta-catenin/Ecadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell, 2001, 105(3), 391-402.
120. Emami, K.H.; Nguyen, C.; Ma, H.; Kim, D.H.; Jeong, K.W.; Eguchi, M.; Moon, R.T.; Teo, J.L.; Kim, H.Y.; Moon, S.H.; Ha, J.R.; Kahn, M. A small molecule inhibitor of beta-catenin/CREBbinding protein transcription [corrected]. Proc. Natl. Acad. Sci. U S A, 2004, 101(34), 12682-12687.
121. Goodman, R.H.; Smolik, S. CBP/p300 in cell growth, transformation, and development. Genes Dev., 2000, 14(13), 1553-1577.
122. Henderson, W.R., Jr.; Chi, E.Y.; Ye, X.; Nguyen, C.; Tien, Y.T.; Zhou, B.; Borok, Z.; Knight, D.A.; Kahn, M. Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc. Natl. Acad. Sci. U S A, 2010, 107(32), 14309-14314.
123. Popadiuk, C.M.; Xiong, J.; Wells, M.G.; Andrews, P.G.; Dankwa, K.; Hirasawa, K.; Lake, B.B.; Kao, K.R. Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer. Clin. Cancer Res., 2006, 12(7 Pt 1), 2216-2223.
124. Salic, A.; Lee, E.; Mayer, L.; Kirschner, M.W. Control of betacatenin stability: reconstitution of the cytoplasmic steps of the wnt pathway in Xenopus egg extracts. Mol. Cell, 2000, 5(3), 523-532.
125. Lee, E.; Salic, A.; Kruger, R.; Heinrich, R.; Kirschner, M.W. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol., 2003, 1(1), E10.
126. Huang, S.M.; Mishina, Y.M.; Liu, S.; Cheung, A.; Stegmeier, F.; Michaud, G.A.; Charlat, O.; Wiellette, E.; Zhang, Y.; Wiessner, S.; Hild, M.; Shi, X.; Wilson, C.J.; Mickanin, C.; Myer, V.; Fazal, A.; Tomlinson, R.; Serluca, F.; Shao, W.; Cheng, H.; Shultz, M.; Rau, C.; Schirle, M.; Schlegl, J.; Ghidelli, S.; Fawell, S.; Lu, C.; Curtis, D.; Kirschner, M.W.; Lengauer, C.; Finan, P.M.; Tallarico, J.A.; Bouwmeester, T.; Porter, J.A.; Bauer, A.; Cong, F. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature, 2009, 461(7264), 614-620.
127. Thorne, C.A.; Hanson, A.J.; Schneider, J.; Tahinci, E.; Orton, D.; Cselenyi, C.S.; Jernigan, K.K.; Meyers, K.C.; Hang, B.I.; Waterson, A.G.; Kim, K.; Melancon, B.; Ghidu, V.P.; Sulikowski, G.A.; LaFleur, B.; Salic, A.; Lee, L.A.; Miller, D.M., 3rd; Lee, E. Smallmolecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat. Chem. Biol., 2010, 6(11), 829-836.
128. Gebhardt, R.; Hovhannisyan, A. Organ patterning in the adult stage: the role of Wnt/beta-catenin signaling in liver zonation and beyond. Dev. Dyn., 2010, 239(1), 45-55.
129. Barraud, L.; Merle, P.; Soma, E.; Lefrancois, L.; Guerret, S.; Chevallier, M.; Dubernet, C.; Couvreur, P.; Trepo, C.; Vitvitski, L. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol., 2005, 42(5), 736-743.
130. Apte, U.; Singh, S.; Zeng, G.; Cieply, B.; Virji, M.A.; Wu, T.; Monga, S.P. Beta-catenin activation promotes liver regeneration after acetaminophen-induced injury. Am. J. Pathol., 2009, 175(3), 1056-1065.
131. Williams, J.M.; Oh, S.H.; Jorgensen, M.; Steiger, N.; Darwiche, H.; Shupe, T.; Petersen, B.E. The role of the Wnt family of secreted proteins in rat oval stem cell-based liver regeneration: Wnt1 drives differentiation. Am. J. Pathol., 2010, 176(6), 2732-2742.
132. Thompson, M.D.; Awuah, P.; Singh, S.; Monga, S.P. Disparate cellular basis of improved liver repair in beta-catenin-overexpressing mice after long-term exposure to 3, 5-diethoxycarbonyl-1, 4-dihydrocollidine. Am. J. Pathol., 2010, 177(4), 1812-1822.
133. Tan, X.; Behari, J.; Cieply, B.; Michalopoulos, G.K.; Monga, S.P. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology, 2006, 131(5), 1561-1572.
134. Zhang, X.F.; Tan, X.; Zeng, G.; Misse, A.; Singh, S.; Kim, Y.; Klaunig, J.E.; Monga, S.P. Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology, 2010, 52(3), 954-965.
135. Rignall, B.; Braeuning, A.; Buchmann, A.; Schwarz, M. Tumor formation in liver of conditional beta-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen. Carcinogenesis, 2011, 32(1), 52-57.
136. Covey, T.M.; Edes, K.; Coombs, G.S.; Virshup, D.M.; Fitzpatrick, F.A. Alkylation of the tumor suppressor PTEN activates Akt and beta-catenin signaling: a mechanism linking inflammation and oxidative stress with cancer. PLoS One, 2010, 5(10), e13545.
137. Cieply, B.; Zeng, G.; Proverbs-Singh, T.; Geller, D.A.; Monga, S.P. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology, 2009, 49(3), 821-831.
138. Lee, T.K.; Castilho, A.; Ma, S.; Ng, I.O. Liver cancer stem cells: implications for a new therapeutic target. Liver Int., 2009, 29(7), 955-965.
139. Bomken, S.; Fiser, K.; Heidenreich, O.; Vormoor, J. Understanding the cancer stem cell. Br. J. Cancer, 2010, 103(4), 439-445.
140. Yoshikawa, H.; Matsubara, K.; Zhou, X.; Okamura, S.; Kubo, T.; Murase, Y.; Shikauchi, Y.; Esteller, M.; Herman, J.G.; Wei Wang, X.; Harris, C.C. WNT10B functional dualism: beta-catenin/Tcfdependent growth promotion or independent suppression with deregulated expression in cancer. Mol. Biol. Cell, 2007, 18(11), 4292-4303.